Controversial Issues and Challenging Cases in Hypertriglyceridemia


Controversial Issues and Challenging Cases in Hypertriglyceridemia

Topic: Cardiology
Relevant Terms: Hypertriglyceridemia, Endocrinology, Lipid Management
Primary Audience: Cardiologists; Internists; Lipidologists; Pharmacists; Registered Nurses; Registered Dietitians; Other Healthcare Professionals
Launch Date: 20-Aug-13
Credits: AMA PRA Category 1 Credit
1 ACPE contact hour
1 ANCC contact hour
1 CDR continuing professional education unit
Expiration Date: The accreditation for this activity has expired.

Learning Objectives

After completing this activity, the participant will demonstrate the ability to:

  1. Describe the pharmacologic differences among the omega-3 fatty acid agents
  2. Assess the potential of new and emerging therapeutic approaches to manage hypertriglyceridemia
  3. Recommend treatment strategies for patients with hypertriglyceridemia based upon evaluation of recent clinical trials
  4. For Registered Nurses and Nurse Practitioners Only: Provide appropriate care and counsel for patients and their families


    Peter P. Toth, MD, PhD, FCCP, FAHA, FACC, Program Chairman
    Director of Preventive Cardiology
    CGH Medical Center
    Sterling, IL
    Professor of Clinical Family and Community Medicine
    University of Illinois School of Medicine
    Peoria, IL
    Professor of Clinical Medicine
    Michigan State University College of Osteopathic Medicine
    East Lansing, MI
    Harold E. Bays, MD, FTOS, FACE, FNLA
    Medical Director/President
    Louisville Metabolic and Atherosclerosis Research Center Inc. (L-MARC)
    Louisville, KY
    Sergio Fazio, MD, PhD, FAAP, FASCI
    Cornelius Vanderbilt Chair of Cardiovascular Medicine
    Professor of Medicine and Professor of Pathology, Immunology, and Microbiology
    Chief, Section of Cardiovascular Disease Prevention
    Vanderbilt University Medical Center
    Nashville, TN
    JoAnne M. Foody, MD, FACC, FAHA
    Medical Director
    Cardiovascular Wellness Program
    Brigham and Women's Hospital
    Associate Professor of Medicine
    Harvard Medical School
    Boston, MA
    Michael Miller, MD, FACC, FAHA
    Departments of Medicine, Epidemiology & Public Health
    University of Maryland School of Medicine
    Director, Center for Preventive Cardiology
    University of Maryland Medical Center
    Baltimore, MD
    Criteria for Success
    This online activity is presented as an enduring internet activity with audio and slide presentations developed from a live symposium activity; the symposium was recorded in May 2013. Statements of credit will be awarded after participants have viewed this CME activity in its entirety, the participant's successful completion of the post-test with a score of 70% or better and completion of the activity evaluation form. If you have questions about this CME/CE activity, please contact the NLA at Please claim credit by August 19, 2014.
    For Pharmacists: Upon receipt of the completed activity evaluation form, transcription information will be available at within 4 weeks.
    Target Audience
    This activity is designed for cardiologists, internists, lipidologists, pharmacists, registered nurses, registered dietitians, and other healthcare professionals involved in the treatment of patients at risk of cardiac events.
    Fee Information
    There is no fee for this educational activity.

    Commercial Support
    This activity is supported by an educational grant from Amarin Pharma Inc.
    Credit Designation
    CME credit provided by the National Lipid Association
    This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of The National Lipid Association and Medtelligence. The National Lipid Association is accredited by the ACCME to provide continuing medical education for physicians. The National Lipid Association designates this enduring internet activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
    Physician Assistants
    NCCPA accepts AMA PRA Category I Credit(s)™ from organizations accredited by ACCME.
    The National Lipid Association is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR). Registered dietitians (RDs) and dietetic technicians, registered (DTRs) will receive 1.0 continuing professional education units (CPEUs) for completion of this program/material.
    CE Credit provided by Postgraduate Institute for Medicine
    Postgraduate Institute for Medicine is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
    Postgraduate Institute for Medicine designates this continuing education activity for 1.0 contact hour (0.1 CEU) of the Accreditation Council for Pharmacy Education.
    Universal Activity Number – 0809-9999-13-309-H01-P (Application)
    Initial Release Date (live symposium): May 30, 2013
    If you received ACPE credit for 0809-9999-13-277-L01-P (Application), you are not eligible to receive ACPE credit for this activity.
    This educational activity for 1.0 contact hour is provided by Postgraduate Institute for Medicine.
    Postgraduate Institute for Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
    Faculty/Planner Financial Disclosures
    Bays, Harold
    Amarin; Amgen; AstraZeneca; Bristol-Myers Squibb; Catabasis; Daiichi Sankyo, Inc.; Eisai; Merck & Co., Inc.; Vivus; WPU; Zeomedex
    Contracted Research
    Amarin; Amgen; Ardena Inc.; Arena Pharmaceuticals; Boehringer Ingelheim; California Raisin Board; Cargill Incorporated; Eisai; Elcelyx; Esperion; Essentialis; Forest; Gilead; Given; GlaxoSmithKline; High Point Pharmaceuticals, LLC; Hoffman LaRoche; Home Access; Merck & Co., Inc.; Micropharma Limited; Nektar; Novartis; Novo Nordisk; Omthera; Orexigen Therapeutics; Pfizer; Pozen; Regeneron; Stratum Nutrition; Takeda; TIMI; Transtech Pharma, Inc.; TWI Bio; Trygg Pharmaceuticals; VIVUS; WPU; Xoma
    Speakers Bureau
    Amarin; Bristol-Myers Squibb; Daiichi Sankyo, Inc.; Eisai; Merck; VIVUS
    Fazio, Sergio
    Advisory Board
    Agerion; Amarin; Kowa; Lupin; Merck; Regeneron; Roche
    Foody, JoAnne
    Amarin; Bristol-Myers Squibb; Gilead; Merck & Co., Inc; Pfizer, Inc; Sanofi-Aventis
    Miller, Michael
    Amarin; Roche
    Toth, Peter
    Amgen; Atherotech; Genzyme; Kowa; Liposcience; Merck
    Speakers Bureau
    Abbvie; Amarin; AstraZeneca; Genzyme; Kowa; Merck
    Medtelligence N/A Ben Caref, PhD has nothing to disclose.
    Nothing to disclose
    PIM planners and managers, Laura Excell, ND, NP, MS, MA, LPC, NCC, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CCMEP, Jan Schultz, RN, MSN, CCMEP, and Patricia Staples, MSN, NP-C, CCRN, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
    Disclosure of Unlabeled Use and Investigational Product
    This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
    Disclosure Declaration
    It is the policy of NLA to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflict of interest is resolved by NLA prior to accreditation of the activity. NLA planners and reviewers have no relevant financial relationships to disclose.
    This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. The NLA specifically disclaims responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through reader's misunderstanding of content.
    Supported Browsers:
    Internet Explorer 8.0+ for Windows 2000, 2003, Vista, XP, Windows 7, Windows 8
    Google Chrome 18.0+ for Windows, Mac OS, or Linux
    Mozilla Firefox 13.0+ for Windows, Mac OS, or Linux
    Safari 4.0+ for Mac OSX 10.5 and above
    Supported Phones & Tablets:
    Android 4.0.3 and above
    iPhone/iPad with iOS 6.1 or above